Latest Asx Market Updates News

Harvest Technology Group is sharpening its focus on defence markets following an independent review that validates its Nodestream platform’s relevance. The company has initiated third-party validation and made significant leadership changes, including the CEO’s departure.

ARC Funds Limited’s trading suspension has been lifted following key announcements about new board appointments, signaling a fresh chapter for the investment manager.

ARC Funds Limited has been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law, raising questions about its governance and future compliance.

Immutep Limited’s shares have resumed trading following the release of an interim futility analysis from its pivotal TACTI-004 Phase III trial of eftilagimod alfa.

Betashares Capital Ltd has announced the Distribution Reinvestment Plan (DRP) issue prices for its February 2026 distribution period, covering two of its popular ETFs. Investors must act quickly to participate before the early March deadline.

Electro Optic Systems has locked in a $100 million secured loan facility to fuel growth and support its acquisition of MARSS, positioning the company for expansion in counter-drone technologies.

IMEXHS Limited delivered FY25 results at the top end of guidance, reporting a 10% revenue increase and a tripling of underlying EBITDA. The company’s software and radiology services both showed solid growth, setting the stage for an optimistic FY26 outlook.

Citigroup Global Markets Australia has announced the record and ex-dividend dates for a fully franked dividend on MFG ordinary shares and its linked CitiFirst Self-Funding Instalment MINI, with dividends directed to reduce outstanding loan amounts.

Austral Resources Australia Ltd has resumed trading on the ASX following news of a significant capital raising and a strategic investor commitment, signaling renewed confidence in the company’s future.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

Celsius Resources Limited has had its trading suspension lifted following an announcement about its Supreme Court application challenging the validity of its prior auditor's 2011 resignation.

Celsius Resources has voluntarily suspended its shares on the ASX pending a Supreme Court ruling on the validity of its former auditor's 2011 resignation. The suspension will last until the court decision or 9 February 2026, whichever comes first.